ClinicalTrials.gov
ClinicalTrials.gov Menu

An Observational Study to Investigate Clinical Usefulness of OROS Hydromorphone in Korean Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01273454
Recruitment Status : Completed
First Posted : January 10, 2011
Last Update Posted : September 4, 2013
Sponsor:
Information provided by (Responsible Party):
Janssen Korea, Ltd., Korea

Brief Summary:
This study aims to collect clinical information and to examine the usefulness and safety of ORal Osmotic System Hydromorphone in Korean cancer patients. The decision to treat patients with drug is as per physician discretion and that doses are determined based upon approved labeling recommendations and physician discretion.

Condition or disease Intervention/treatment
Pain Drug: OROS Hydromorphone

Detailed Description:
The primary purpose of this observational study is to collect clinical data on cancer pain control using OROS (ORal Osmotic Active System) hydromorphone and to investigate the clinical usefulness of OROS hydromorphone for Korean cancer patients. Information on the effectiveness of cancer pain control and any adverse events reported by those patients using OROS Hydromorphone will be reported. In addition, clinical usefulness of OROS hydromorphone will be evaluated through assessing sleep disturbance due to pain, breakthrough pain, and end-of-dose failure before and after the study drug administration and examining the patient's satisfaction with study drug and the investigator's global assessment. This is a multi-center, open-label, prospective, exploratory, and observational study with approximately 770 patients. Efficacy endpoints will be analyzed to examine the difference between before and after the treatment. Since this is an observational study under the condition of routine practice, OROS Hydromorphone dosage should be adjusted at the discretion of the investigator, based on patient response. It is recommended that the dosage be conservative at first and adjusted appropriately considering the adverse events and analgesic effect for all the patients.

Study Type : Observational
Actual Enrollment : 648 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: An Open-label, Multi-center, Non-interventional Study to Investigate Clinical Usefulness of Hydromorphone OROS in Korean Cancer Patients
Study Start Date : June 2009
Actual Primary Completion Date : December 2009
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort Intervention/treatment
001
OROS Hydromorphone 8 16 32 mg once a day for 4 weeks
Drug: OROS Hydromorphone
8,16, 32 mg once a day for 4 weeks



Primary Outcome Measures :
  1. Change in pain intensity score (where 0 is worst and 10 is best) as measured on the Numeric Rating Scale (NRS) from baseline to Day 36 [ Time Frame: Between Visit 1 (day 1) and the last visit (day 29 ± 7: from day 22 to day 36) ]

Secondary Outcome Measures :
  1. Change in sleep disturbance [ Time Frame: between Visit 1 (DAY 1) and the last visit (DAY29 ± 7: from 22 day to 36 day)) ]
  2. Breakthrough pain experience [ Time Frame: between Visit 1 (DAY 1) and the last visit (DAY29 ± 7: from 22 day to 36 day)) ]
  3. End-of-dose failure experience [ Time Frame: between Visit 1 (DAY 1) and the last visit (DAY29 ± 7: from 22 day to 36 day)) ]
  4. Patient satisfaction with study drug and detailed reason [ Time Frame: at the last visit (DAY29 ± 7: from 22 day to 36 day)) ]
  5. Investigator's global assessment [ Time Frame: the last visit (DAY29 ± 7: from 22 day to 36 day) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients suffering from cancer pain who visit the study sites during study and eligible to be treated with OROS hydromorphone at the discretion of the investigator.
Criteria

Inclusion Criteria:

  • Patients who are in need OROS hydromorphone to relieve cancer pain

Exclusion Criteria:

  • Patients with serious gastrointestinal diseases that may interfere with oral analgesic effects, such as dysphagia, vomiting, absence of periastalsis, intestinal obstruction, and/or severe strangulation, in which case the absorption and passage of orally-administered medication may be unduly influenced

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01273454


Sponsors and Collaborators
Janssen Korea, Ltd., Korea
Investigators
Study Director: Janssen Korea, Ltd. Clinical Trial Janssen Korea, Ltd.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Janssen Korea, Ltd., Korea
ClinicalTrials.gov Identifier: NCT01273454     History of Changes
Other Study ID Numbers: CR016324
First Posted: January 10, 2011    Key Record Dates
Last Update Posted: September 4, 2013
Last Verified: September 2013

Keywords provided by Janssen Korea, Ltd., Korea:
Open-label
Non-interventional
OROS hydromorphone
Korean cancer patients

Additional relevant MeSH terms:
Hydromorphone
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents